Free shipping on all orders over $ 500

Ponezumab

Cat. No. M24568
Ponezumab Structure
Synonym:

PF-04360365; RN 1219

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Ponezumab (PF-04360365) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab can be used in study of Alzheimer's disease.

Chemical Information
CAS Number 1178862-65-1
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Claire Leurent, et al. Ann Clin Transl Neurol. Immunotherapy with ponezumab for probable cerebral amyloid angiopathy

[2] Jaren W Landen, et al. Alzheimers Dement (N Y). Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study

[3] Jaren W Landen, et al. Alzheimers Dement (N Y). Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy

[4] Aaron H Burstein, et al. Clin Neuropharmacol. Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease

[5] Gary B Freeman, et al. J Alzheimers Dis. 39-week toxicity and toxicokinetic study of ponezumab (PF-04360365) in cynomolgus monkeys with 12-week recovery period

Related EGFR/HER2 Products
Zongertinib

Zongertinib (BI 1810631) is a human HER2-selective tyrosine kinase inhibitor that covalently binds to both wild-type and mutated HER2 receptors, including exon 20 insertion mutations, whilst sparing EGFR signaling. Zongertinib has antitumor activity.

Inetetamab

Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab shows antitumor activities when used alone or together with tyrosine kinase inhibitors.

BBT-207

BBT-207 is a reversible, mutant-specific EGFR inhibitor with antitumor activity.

VRN-11

VRN-11 is an EGFR C797S inhibitor.

TRX-221

TRX-221 is an EGFR C797S inhibitor.

  Catalog
Abmole Inhibitor Catalog




Keywords: Ponezumab, PF-04360365; RN 1219 supplier, EGFR/HER2, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.